Endocrine Therapy Plus Bevacizumab Shows Benefit in ER+/HER2- Breast CancerMay 12th 2022
Endocrine therapy plus bevacizumab with the possibility of weekly paclitaxel reinduction signals efficacy and demonstrates a good safety profile in patients with ER-positive, HER2-negative advanced or metastatic breast cancer who have responded to induction therapy.
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Unresectable HER2+ mBCMay 4th 2022
Fam-trastuzumab deruxtecan-nxki has been approved by the FDA for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.
Ribociclib Demonstrates Promising OS Benefit in HR+/HER2- Advanced Breast CancerMay 4th 2022
Combination of ribociclib plus fulvestrant achieved a median overall survival of 67.6 months in the first-line setting for patients with postmenopausal, hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
Trial of Odetiglucan Plus Pembrolizumab for Metastatic Breast Cancer Starts DosingApril 29th 2022
Treatment with the combination of odetiglucan or Imprime PGG and pembrolizumab had begun in patients with metastatic hormone-refractory breast cancer who are enrolled in a phase 2 clinical trial.
CDK 4/6 Inhibitors Show Efficacy in HR+ MBC With ESR1 MutationsApril 27th 2022
Jamie Brett, resident in internal medicine at Massachusetts General Hospital, discusses the effectiveness of CDK4/6 for patients with hormone receptor-positive metastatic breast cancer (MBC) with ESR1 mutations and fusions.
POLL: What Treatment Would You Choose for BRCA-, PD-L1- Metastatic TNBC?April 25th 2022
Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.
Roundtable Discussion: Exploring CDK Inhibition in HR+, HER2– Early-Stage Breast CancerApril 25th 2022
During a case-based roundtable event, Kevin Kalinsky, MD, MS, discussed clinical typing of patients with breast cancer and the results of trials of therapies for patients with HR-positive, HER2-negative breast cancer.
Real-World Analysis of THP in mBC Shows Similar Survival, Safety Outcomes to CLEOPATRA TrialApril 13th 2022
Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial.
Elimusertib Elicits Response in Patients With Solid Tumors and ATM/BRCA1/2 DefectsApril 11th 2022
According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.
Roughly 15% of Nonclonal Recurrent DCIS Cases May Be Undertreated, Research SuggestsApril 10th 2022
According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.
New Guidelines Move Beyond Chemotherapy for Patients With Triple-Negative Breast CancerMarch 30th 2022
The NCCN recommendations concerning the management of patients with TNBC have been updated for various settings, including early, recur- rent and unresectable, BRCA1/2-mutated, and high-risk triple-negative breast cancer.
Dietrich Analyzes Study Results in Early-Stage Breast Cancer TreatmentsMarch 23rd 2022
During a Targeted Oncology case-based roundtable event, Martin Dietrich, MD, PhD, discussed the MonarchE trial of abemaciclib and the agent's use in high-risk, early-stage breast cancer.
Behind the FDA Approval: Adjuvant Olaparib for BRCA+/HER2- Breast CancerMarch 22nd 2022
In an interview with Targeted Oncology, Charles Geyer, MD, discussed the data from the OlympiA clinical trial and how adjuvant olaparib could impact the treatment of BRCA-positive, HER2-negative breast cancer and other BRCA-positive women’s cancers.
Roundtable Discussion: Isaacs Discusses Second- and Third-Line Therapy for Patients with TNBCMarch 21st 2022
During a Targeted Oncology case-based roundtable event, Claudine Isaacs, MD, discussed treatment options for a patient with triple-negative breast cancer whose condition worsened after first-line gemcitabine plus carboplatin.
OlympiA Update Shows Full Picture of Survival Benefit With Adjuvant Olaparib in BRCA+/HER2- High-Risk Early Breast CancerMarch 16th 2022
Three and a half-year follow-up in the OlympiA trial showed continued survival improvement and underscores the vitality of germline BRCA testing.
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast Cancer
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Case 3: POETIC and ADAPT Trials in HR+ High-Risk Breast Cancer
Joyce O’Shaughnessy, MD, reviews the case of a 42-year-old woman with node-positive, HR-positive high-risk breast cancer and discusses clinical data from the POETIC and ADAPT clinical trials.
FDA Approves Olaparib CDx to Detect BRCA in High Risk Early Breast CancerMarch 14th 2022
The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.
Ribociclib Plus Letrozole Extends Survival in Patients With Metastatic Breast CancerMarch 11th 2022
Ribociclib plus letrozole demonstrated statistically significant improvement in overall survival with the combination in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
Sacituzumab Govitecan Prolongs PFS in HR+/HER- Metastatic Breast CancerMarch 8th 2022
In the phase 3 TROPICS-02 clinical trial, sacituzumab govitecan demonstrated a 30% reduction in the risk of disease progression or death versus chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.